Introduction
AKT1 (protein kinase B, α), a serine/threonine kinase of the AKT family, is involved in multiple biological processes and several severe psychiatric disorders including schizophrenia and methamphetamine (Meth) use disorders. Accumulating evidence from human genetic studies suggests that the AKT1 gene is associated with the genetic etiology of schizophrenia in Caucasian families of European descent 1 and several other ethnic groups. 2 Positive associations between several haplotypes of AKT1 and Meth abuse/dependence have also been reported in the Japanese population 3 and in a systematic review study. 4 It is known that Meth, a dopamine enhancer and a potent illicit psychostimulant, can cause psychotic symptoms indistinguishable from schizophrenia in abusers and aggravate psychosis in patients with schizophrenia. 4, 5 Meth users and schizophrenic patients also share some similarities in their numerous sex-based differences, [6] [7] [8] [9] and some sex-specific behavioral deficits have been recapitulated in Akt1-deficient mice. 10 Interestingly, estrogen signaling, an important cause of sex differences, may be disturbed in schizophrenic patients, 11, 12 and estrogen treatment can also ameliorate schizophrenia symptoms. 13, 14 Accordingly, the "estrogen protection hypothesis" has been proposed to account for these gender differences and suggests that estrogen provides protection from the development of schizophrenia and mitigates schizophrenic symptoms.
Abnormalities in the dopamine system (or the dopamine hypothesis) have long been implicated in explanations of schizophrenia and Meth-associated psychosis. 15 Studies of the postmortem brains of schizophrenic patients, 1, 16 Akt1-deficient mice, 10, 17 and functional neuroimaging in humans 18 support the idea that genetic variations in AKT1 or its protein have epistatic effects on the regulation of dopamine-dependent functions or drug effects. Emerging evidence also indicates that AKT is directly downstream of dopamine D2 receptor (DRD2) activation and DRD2-mediated AKT interacts with the β-arrestin2/PP2A signaling complex in the regulation of dopamine signaling cascades and the expression of dopamine-dependent behaviors, especially in the striatum. [19] [20] [21] Anatomically, the striatum, the principal input structure of the basal ganglia that influences motor control and reward-based learning, receives prominent dopaminergic inputs from the midbrain through the mesocorticolimbic and nigrostriatal dopamine systems. 22, 23 The striatal medium spiny neurons (MSNs) are the principal (over 95%) neurons in the striatum and act as the main output neurons to form the predominantly gamma-aminobutyric acidergic (GABAergic) microcircuit. 24 The impact of AKT1 on MSNs remains unclear, but AKT-mediated phosphorylation has been reported to regulate synaptic strength and synaptic plasticity through an increase of the number of GABA A receptors. 25 Thus, activation of AKT1 might interact with the dopaminergic system to regulate striatal MSNs, and this could eventually lead to abnormalities in striatum-dependent behaviors or the pathogenesis of psychiatric disorders such as schizophrenia and Meth use disorders.
Meth-associated psychosis has been considered to be a pharmacological or environmental disease that produces an agent model of schizophrenia due in part to similarities in clinical presentation and response to treatment. In the context of drug addiction and schizophrenia, the behavioral sensitization model is well established and widely used in laboratory animals. 26, 27 In rodents, repeated systemic Meth/amphetamine administrations not only result in enduring sensitized behaviors (such as enhanced locomotor activity, more rapid onset, and greater intensity of stereotypy) in response to subsequent Meth/amphetamine challenges but also result in elevated striatal dopamine release. [28] [29] [30] [31] This experimental procedure provides a potential animal model to test the impact of AKT1 deficiency in the regulation of dopamine-related sensitization and its susceptibility to schizophrenia-related symptoms and Meth-associated psychosis, especially in mutant mouse models.
Given the involvement of AKT1 in the dopamine signaling cascade and in the pathogenesis of Meth abuse disorder and schizophrenia, we conducted a series of 4 experiments to investigate the sex-specific role of Akt1 in the regulation of dopamine-dependent behavior and striatal activity by measuring Meth-induced alterations in behavioral sensitization (experiment 1) and brain activity using small animal positron emission tomography (microPET) scan (experiment 2). Basal levels of neurotransmitters and basal electrophysiological/neuromorphological properties of striatal MSNs were further examined to characterize basal differences between male Akt1 −/− mice and their wild-type (WT) controls (experiment 3). A series of daily injections of 17β-estradiol was applied to further examine the "estrogen protection hypothesis" in Meth-treated male mice (experiment 4).
Materials and Methods

Animals
All Akt1 homozygous knockout (Akt1
−/−
) and WT mice used in this study were generated from Akt1 heterozygous breeding pairs with a C57BL/6J genetic background (n > 10). The details have been described elsewhere 10, 17, 32 and in the online supplementary Methods.
Experiment 1A: Evaluation of Meth-Induced Behavioral Sensitization
Meth-induced behavioral sensitization was used to evaluate dopamine-related behavioral alterations in male and female Akt1 −/− mice and their WT littermates (n = 8-10 each, 4 months old). The behavioral sensitization procedure (modified from) 33 consisted of 6 daily injections of Meth (from Food and Drug Administration, Department of Health, Taipei, Taiwan; 2.0 mg/kg, ip, dissolved in saline), followed by 1 day of withdrawal and a 1.0 mg/ kg Meth challenge on day 8. The locomotor activity of each mouse was recorded and analyzed using Ethovision video tracking system (Noldus Information Technology, Wageningen, Netherlands) on days 1, 3, 6, and 8. On the days of measurement of locomotor activity, the total distance traveled (cm) by each mouse was recorded in a polyvinylchloride chamber (48 × 24 × 25 cm) for a 60-min baseline period, followed by a 15-min saline baseline after a saline injection, and then 60 min of locomotion was recorded after the injection of Meth.
Experiment 1B: Coinjections of Meth With Dopaminergic Antagonists in Meth-Sensitized Mice
To further examine the sex-specific effect of Akt1 on the regulation of dopamine D1-/D2-like receptor-dependent suppression of Meth-induced hyperlocomotion, Methsensitized mice from the previous experiment were further challenged by the coinjection of Meth (1.0 mg/kg), with an optimal effective dose of raclopride (from SigmaAldrich, a dopamine D2-like receptor antagonist, 1.0 mg/ kg, ip) on day 10 and SCH23390 (from Sigma-Aldrich, a dopamine D1-like receptor antagonist, 0.01 mg/kg, ip) on day 12. A 1-day washout interval between treatments was applied to avoid any carryover effect. On each testing day, locomotor activity was measured as described above. The net value of suppressed locomotion is equal to the difference between locomotion induced by coinjections on the testing day and Meth-induced locomotion on day 8.
Experiment 2: Evaluation of Brain Activity Using MicroPET Scanning
Male and female Akt1 -/-mice and their WT littermates (n = 5 each) were used to evaluate brain activity using microPET scans (eXplore Vista DR, GE Healthcare) with 18 F-fluorodeoxyglucose (FDG). Each mouse received a baseline PET-CT (FDG) scan and another PET-CT scan after Meth administration (4 mg/kg, ip, FDG + Meth) 7-10 days later. A slightly higher dose of Meth was used here to ensure that acute Meth-induced brain activities can be successfully detected using animal PET scan. Five regions of interest (ROI, including the medial prefrontal cortex (mPFC), caudate putamen (CPu), nucleus accumbens (NAc), total striatum (CPu + NAc), and cerebellum) were selected. The average standardized uptake values (SUV) of each ROI were obtained, and the normalized SUV was calculated as SUV target ROI /SUV cerebellum . The ratio of Meth-induced brain metabolic change in each dopamine-related ROI was further calculated as normalized SUV FDG + Meth /normalized SUV FDG . The basic method has been described previously, 34 and details are presented in the online supplementary Methods.
Experiment 3A: Examination of Basal Levels of Neurotransmitters and Their Metabolites in the Brain of Male Mice
The basal levels of L-dopa, dopamine, norepinephrine, serotonin, and their metabolites were measured using high-performance liquid chromatography in the frontal cortex, striatum, somatosensory cortex, hippocampus, and midbrain of male Akt1 -/-and WT littermate mice (n = 8 each). The method has been described previously, 35 and details are presented in the online supplementary Methods.
Experiment 3B: Examination of Basal Electrophysiological and Neuromorphological Properties of Striatal MSNs in Male Mice
Male Akt1
-/-and WT mice (approximately 8 weeks old) were used in this experiment. Striatal MSNs were identified in coronal forebrain slices, 36, 37 and their electrophysiological and morphological properties were recorded with patch pipettes. Miniature excitatory/inhibitory postsynaptic currents (mEPSCs/mIPSCs) activity, which is caused by spontaneous and random release of glutamate/GABA from presynaptic vesicles in the absence of an action potential, was recorded to examine the excitatory/inhibitory synaptic inputs to the MSNs. The recorded neurons were labeled with biocytin during recording and visualized with biocytin labeling. The neurons were reconstructed using the Neurolucida system (MBF Bioscience). For each available neuron (n = 10), we measured the morphological variables and performed a Sholl analysis to evaluate the dendritic complexity. 10, 17 All details are described in the online supplementary Methods.
Experiment 4: Evaluation of the Effect of 17β-Estradiol on the Rescue of Meth-Induced Hyperlocomotion in Male Akt1
-/-Mice
In this experiment, the protective effect of 17β-estradiol was evaluated in Meth-treated male mice. Another batch of 4 month-old male Akt1 -/-mice and their WT littermates was used in this experiment, and they were randomly assigned to one of the following 6 treatment groups (n = 11-13 each): (1) -/-mice with Estradiol and Meth injections (Akt1-Estradiol-Meth group). The same behavioral sensitization procedure was applied as described above, and the males in each group received different treatments accordingly. From 4 days before to the first day of behavioral sensitization (total 12 days), each subject in the 3 VEH groups received a subcutaneous injection of 0.1 ml of vehicle (0.9% saline with 0.3% gelatin) twice per day (12 h apart), and each male in the 3 Estradiol groups received 2 daily (12 h apart) injections of 1 μg (in 0.1 ml of vehicle) of 17β-estradiol (Sigma-Aldrich) as described previously. 38 As described before, Meth was dissolved in saline and administered intraperitoneally. The same recording method described above was used, and locomotor activity was recorded on days 1, 3, 6, and 8 of behavioral sensitization.
Statistics and Data Analyses
All of the data are presented as the mean + SE of the mean (SEM). Statistical analyses were performed using SPSS 13.0 (SPSS Inc.), and the data were analyzed by 1-way or 2-way ANOVAs or 2-sample Student's t test, where appropriate. A post hoc analysis was performed using Fisher's Least Significant Difference (LSD) test when the F values revealed a significant difference. A priori t tests (with Bonferroni adjustments when needed) were conducted to compare genotypic differences or to answer specific hypotheses. The comparisons of mEPSCs/mIPSCs were made using the KolmogorovSmirnov test to test whether any 2 of the distributions were identical. The details of statistical analysis for in vitro data were described in the online supplementary Methods. P values of < .05 were considered statistically significant.
Results
Experiment 1A: Sex-Specific Effect of Akt1 on MethInduced Behavioral Sensitization
During the 6-day acquisition of Meth-induced behavioral sensitization, no significant genotypic differences were found among males or females. Over days, both WT and Akt1 −/− mice exhibited progressively more rapid onset to the peak of Meth-induced hyperlocomotion across days 1, 3, and 6 in males (F (2, 26) = 111.355, P = .0001 < .05) and females (F (2, 32) = 104.442, P = .0001 < .05), as depicted in online supplementary figures 1A and 1B. Compared with the 15-min saline baseline, the treatment of Meth induced significantly greater locomotor activity 15 min after injection in all groups on each testing days (see online supplementary figures 1C and 1D). Priori t tests further revealed that Meth-induced hyperlocomotion on day 3 or day 6 was significantly greater than the one on day 1 for both WT and Akt1 −/− male and female mice (all P < .05). The results indicated that these mice demonstrated behavioral sensitization to Meth over days. On day 8 (the challenge day), no significant genotypic differences were found during the 60-min baseline (figure 1A) or during the 15-min saline baseline. However, priori t tests revealed that half dose of Meth challenge (ie, 1 mg/kg) induced significantly or marginally higher hyperlocomotion on day 8 compared with Methinduced hyperlocomotion on day 6 in WT females (51 202 .01 ± 2096.508 vs 47 069.46 ± 2368.167 cm, t (9) = 3.373, P = .008), Akt1 −/− females (50 204.251 ± 3113.698 vs 43 961.926 ± 3887.944 cm, t (7) = 5.683, P = .0007), and WT males (48 704 .637 ± 1740.095 vs 42 465.181 ± 4080.21 cm, t (7) = 2.038, P = .08). In contrast, Akt1 −/− males did not displayed significantly enhanced Meth-induced hyperlocomotion on day 8 compared with the one on day 6 (40 083.946 ± 1856.684 vs 39 178.361 ± 2333.7 cm; t (7) = 0.31, P = .77). These findings indicated that all but male Akt1 −/− mice fully developed Meth-induced behavioral sensitization on day 8. Furthermore, as depicted in figure 1A , there were also significant main effects of genotype (F (1,29) = 4.875, P = .0353) and sex (F (1,29) = 8.05, P = .0082) for Meth-induced hyperactivity on day 8. The genotype × sex interaction was not statistically significant, but there was a trend toward statistical significance (F (1,29) = 3.202, P = 0.084). Fisher's LSD post hoc analysis further indicated that male Akt1 −/− mice displayed significantly decreased Meth-induced hyperactivity compared with male WT controls (P < .05), whereas female mice did not show this genotypic difference. Accordingly, the following data were analyzed separately by sex.
Experiment 1B: The Sex-Specific Effect of Akt1 Was Further Revealed by Coinjections of Meth With Raclopride in Meth-Sensitized Mice
The net effects of raclopride and SCH23390 on the suppression of Meth-induced hyperlocomotion in males and females are shown in figures 1B and 1C, respectively. In the males, the coinjection of raclopride resulted in a significant suppression of Meth-induced hyperlocomotion in WT mice compared with Akt1 −/− mice (t (13) = −2.25, P = .042), whereas the coinjection of SCH23390 had no effect. In contrast to males, no significant genotypic difference was found in the females. These results indicate that raclopride (but not SCH23390) can exert its suppression effect on Meth-induced hyperlocomotion by acting on Akt1 and its downstream signaling, especially in the males. They also underline the importance of Akt1 in the modulation of DRD2-dependent signaling and dopamine-dependent behavior.
Experiment 2: Sex-Specific Effect of Akt1 in the Regulation of Meth-Induced Brain Activity Was Confirmed in the Striatum Using MicroPET With 18 F-FDG
Representative microPET images of a mouse brain are shown in figure 2A , and regions of interest are illustrated in figure 2B . At the basal level, neither the male nor female mice displayed significant genotypic differences in their normalized SUV in any ROI (all P > .05, data not shown). In contrast, the ratio of Meth-induced brain metabolic change exhibited some significant genotypic differences in the CPu, NAc, and mPFC of the male mice (figure 2C), whereas no differences were found in the female mice ( figure 2D ). These microPET results indicated a region-and sex-specific reduction of Methinduced activity in the brain of Akt1 −/− males, especially in the striatum at 30-60 min after injection of FDG.
Experiment 3A: Quantification of Basal Levels of Neurotransmitters and Their Metabolites in the Brains of Male Mice
As indicated in online supplementary table 1, among the 5 brain areas we examined, no significant genotypic differences in basal levels of neurotransmitters or their metabolites were found with the exception of norepinephrine. In comparison with WT controls, Akt1 −/− mice had significantly higher levels of norepinephrine in the frontal cortex and midbrain (both P < .05).
Experiment 3B: Altered Intrinsic Electrophysiological and Neuromorphological Properties of Striatal MSNs in Male Akt1
−/− Mice A representative image of a biocytin-labeled striatal MSN is shown in figure 3A . As indicated in table 1, concerning the intrinsic membrane properties, the Akt1 −/− group had slightly higher resting membrane potentials (t (35) = 2.776, P = .009) and significantly higher input resistances (t (78) = −3.426, P = .001) than those of the WT group. Regarding the firing patterns, the rheobase was significantly lower in the Akt1 −/− group compared with the WT group (t (80) = 2.133, P = .036). The current-firing frequency (I-ΔV) plot for the Akt1 −/− group displayed a significant shift to the left (F (1,90) = 4.783, P < .05), and its firing frequency increased significantly in response to multiple injected currents compared with the results obtained for the WT controls (P < .05, figure 3B ). No genotypic differences were found in the input-output relationship or the input/output gain.
Besides, representative traces of striatal MSNs from WT and Akt1 −/− mice are shown in figure 3C . As indicated in table 1, there were significant decreases in the number and average length of primary dendrites in Akt1 −/− mice compared with WT controls (t (18) = 3.562, P = .002 and t (18) = 2.238, P = .038, respectively). The Sholl analysis also indicated an overall genotypic effect (F (1, 20) = 4.539, P < .05) and a significant alteration of the crossing numbers at varying distances from the soma in Akt1 −/− mice ( figure 3D) .
Furthermore, as depicted in figures 3E and 3F, alteration of GABAergic, but not glutamatergic, inputs to striatal MSNs was found. Representative current traces of mEPSCs and mIPSC are shown in figures 3E-1 and 3E-2, respectively. No genotypic difference was found in the interevent interval (frequency) or the amplitude of the mEPSCs (figures 3E-2 and 3E-3). In contrast to glutamatergic inputs, GABA A receptor-mediated mIPSCs in striatal MSNs were significantly affected. A significantly lower interevent interval (ie, higher average frequency) was observed in Akt1 −/− mice, indicating an increase in the presynaptic release probability or the number of synaptic inputs ( figure 3F-2) . A significant reduction of the cumulative nature of the miniature amplitudes was also observed in Akt1 −/− mice, indicating that the overall levels of functional GABA A receptors on the postsynaptic membrane were altered ( figure 3F-3) . These findings suggest that the deficiency of Akt1 might affect inhibitory, but not excitatory, neurotransmission at both pre-and postsynaptic sites of striatal MSNs.
Experiment 4: Daily Injections of 17β-Estradiol Prevented the Reduction of Meth-Induced Hyperactivity in Male Akt1
−/− Mice As depicted in figure 4 , there were significant differences among the 6 groups (F (5,67) = 93.715, P = .0001), and all Meth-injection groups displayed significant hyperlocomotion on the challenge day compared with the salineinjection groups. As reported previously, Akt1 deficiency resulted in the significant reduction of Meth-induced hyperlocomotion in Akt1 −/− mice (P = .008; WT-VEHMeth group vs Akt1-VEH-Meth group). By contrast, daily injections of 17β-estradiol did not affect Methinduced hyperlocomotion in WT mice (WT-VEH-Meth group vs WT-Estradiol-Meth group). However, compared with the Akt1-VEH-Meth group, such treatment significantly prevented the reduction of Meth-induced hyperlocomotion in the Akt1-Estradiol-Meth group (P = .0001).
Discussion
The use of genetically modified mice that carry an alteration of the Akt1 gene as an experimental tool offers an alternative model to mimic the reduction of AKT1 in some schizophrenic patients 1, 16 and provides a feasible model to characterize the effect of Meth in Akt1-deficient mice. The sex-specific effect of Akt1 on the regulation of Meth-induced behavioral sensitization and striatal activity found in this study is of great interest. Our data consistently indicated that Akt1 deficiency dampens dopamine-dependent responses and that this phenomenon is evident in males only. In contrast, some sex-specific behavioral deficits were also found in drug-free, Akt1-deficient female mice. 10 As mentioned previously, gender differences have been reported in both Meth use disorders 8 and schizophrenia. 7 The "estrogen protection hypothesis" has been proposed and indicates that estrogen might exert a neuroprotective effect against several disease models and human disorders, including schizophrenia and Meth use disorders. Our findings appear to recapitulate some of these sex differences in Akt1 −/− mice and support the involvement of AKT1 in the sex differences of these 2 disorders. Furthermore, numerous studies have demonstrated that estrogen exerts neuroprotective effects against ischemia and apoptosis via estrogen receptors and activation of insulin/PI3K/ AKT pathway. [39] [40] [41] [42] In vitro studies using transient Akt1 transfection, Akt inhibitor, and dominant-negative Akt1 further revealed that Akt1 kinase activity is required for the upregulation of estrogen receptor α by modulating association of these receptors to the target gene promoters. 43 The importance of AKT in the suppression of estrogen receptor α-mediated transcription and in estrogen-stimulated synaptogenesis was also reported. 44, 45 Similar to AKT1, accumulating studies have confirmed the importance of 17β-estradiol in regulating structural plasticity through direct or indirect effects on dendritic and axonal morphology, 46 and the estrogen receptor α gene also exhibits a positive association with schizophrenia. 12 Interestingly, in this study, the reduction of Meth-induced hyperlocomotion can be prevented by subchronic injections of 17β-estradiol, the most potent of the mammalian estrogenic steroids, in Akt1 −/− males. However, 17β-estradiol alone has no effect on the alteration of locomotion or Methinduced hyperlocomotion in our male WT mice. These findings suggest that estrogen might play a role in the regulation of dopamine-dependent signaling cascade and Meth-induced behavioral sensitization in the absence of Akt1 in male mice. Thus, in addition to the above-mentioned estrogen-mediated neuroprotection by Akt1, the modulatory effect of estradiol on dopamine signaling could be independent of the AKT1 pathway. Estrogens might compensatively upregulate other dopamine signaling pathways (eg, cAMP/PKA/ DARPP-32, MAPK, or CREB signaling) or other related genes through genomic regulations, as suggested previously, 47, 48 to enhance dopamine-dependent responses. Future research in this area would be timely and greatly worthwhile.
Additionally, the sex-specific role of Akt1 in the modulation of Meth was further confirmed by coinjections of Meth with a DRD2 antagonist and measures of Methinduced striatal activity using microPET. Coinjections of Meth with raclopride, but not SCH23390, significantly dampened Meth-induced hyperlocomotion in WT males but was less effective in male Akt1 −/− mice, indicating the importance of Akt1 and DRD2 in the modulation of Meth-dependent hyperlocomotion in male mice. As described previously, compelling evidence from both human and mouse studies suggests that genetic variations in AKT1 or AKT1 protein have epistatic effects on the regulation of dopamine-dependent functions or drug effects. 1, 10, 17, 18 AKT was also reported to participate in the DRD2-dependent AKT-β-arrestin2-PP2A complex and to regulate the expression of dopamine-associated behaviors. [19] [20] [21] Our data further highlight AKT1's (rather than the other 2 isoforms) important role in the regulation of dopamine-dependent responses. However, the deficiency of Akt1 in male mice did not alter basal levels of neurotransmitters among the 5 brain areas we examined. The enhancement of norepinephrine release in the frontal cortex and midbrain of Akt1 −/− mice is somewhat unexpected. It could be due to the possibility of regionspecific compensation in Akt1 −/− mice, as reported previously using in vivo microdialysis to reveal an increase in the basal level of extracellular dopamine in prefrontal cortex. 17 Furthermore, our microPET data not only reconfirm the importance of Akt1 in the dopaminedependent signaling cascade but also provide regionaland temporal-specific evidence to support the previously proposed AKT/GSK3-dependent, long-lasting wave of Meth-induced parallel responses in the striatum of mice. 20 These findings suggest that the striatum is highly involved in the observed differences in Meth-treated males and imply that postsynaptic MSNs in the striatum might play an important role in the regulation of Akt1-related psychomotor functions in these mice.
Among the electrophysiological/morphological properties of striatal MSNs that we examined in this study, Akt1 −/− mice exhibited higher input resistance and lower rheobases compared with WT controls. As expected, 
MSNs in Akt1
−/− males were more excitable, and they generated action potentials easily than their WT controls. However, MSNs in both groups displayed similar firing patterns once the depolarizing currents exceed their rheobases. Additionally, it was reported that activation of AKT increased the number of postsynaptic GABA A receptors and receptor-mediated synaptic transmission. 25 The reduction of the amplitude of mIPSCs in Akt1 −/− males further implied that the function of GABA A receptors was downregulated in their striatal MSNs and that there might be an imbalance of the excitatory and inhibitory synaptic inputs to MSNs in Akt1 −/− mice. Considering the intrinsic membrane properties and the measurement of miniature currents together, these alterations seem to exert similar effects and lead to an enhanced excitability of postsynaptic MSNs in Akt1-deficient mice. Furthermore, AKT has been found to be involved in several features of neurite outgrowth including elongation, branching, and caliber 49 that may affect the electrophysiological properties of neurons. Indeed, neuromorphological alterations of GFP-labeled pyramidal neurons in Akt1 −/− mice have been reported previously in the medial prefrontal cortex 17 and the auditory cortex. 10 Our current data further revealed that striatal MSNs in Akt1 −/− males also had region-specific alterations. These neuromorphological changes might at least partially account for the observed alterations in electrophysiological properties and input resistances. Although we did not separately record D1-/D2-like receptors of MSNs in this study because these 2 subgroups are morphologically indistinguishable and mosaically distributed, 50 the observed alternations in striatal MSNs are more likely to be related to the striatopallidal MSNs 50, 51 and express the D2-like receptors that reduce the output of MSNs. [52] [53] [54] In conclusion, our data revealed a sex-and regionspecific role of Akt1, a schizophrenia susceptibility gene, in the modulation of dopamine-dependent behavior and striatal neuronal activity. We also found that 17β-estradiol has a protective effect against the reduction of Meth-induced hyperlocomotion in Methsensitized Akt1 mutant males. As proposed by Kapur et al. in a revised theory based on the dopamine hypothesis of psychosis, striatal dopamine dysregulation could alter the appraisal of stimuli through a process of aberrant salience and eventually lead to psychosis. 15, 55, 56 Accordingly, the alterations of the electrophysiological and neuromorphological properties of striatal MSNs in Akt1 mutant mice might be responsible for some psychomotor functions that we reported in this study and for those dopamine-related cognitive dysfunctions (eg, aberrant motivational salience and reward prediction error) that we reported recently. 35 Our study highlights the importance of AKT1 in the dopamine-dependent response and sensitivity to Meth, which might, at least in part, account for the pathogenesis of Meth-induced psychosis and Meth abuse. Our findings also imply that the AKT1 deficiency could result in reduced Meth sensitivity and Meth-induced brain activity in male Meth users. Behavioral and physiological compensation might occur in these vulnerable individuals. The reduction could evoke higher doses or repeated use of Meth to overcome such deficit but lead to higher abuse potential or more severe Meth-induced psychosis state. In the future studies, many follow-up experiments can be carried out accordingly. Further exploration and confirmation of the roles of estrogen (or other sex hormones) in the regulation of Meth-induced hyperlocomotion or schizophrenia-like symptoms using Akt1 or other mutant mice is warranted too. 
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